Stargardt's disease

6 trials MedDRA PT
6 Registered trials
0 Recruiting
5 Unique sponsors
4 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase III: 2 Phase II: 1 Phase I (Other): 1 Phase I (First in Human): 2

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

2 trials
  • Belite Bio Inc. Commercial
    TINLAREBANT
    2024-513483-26-00 4 countries 2022 n=9 Orphan
    Ended
  • Belite Bio Inc. Commercial
    TINLAREBANT
    2025-522460-33-00 3 countries n=6 Orphan
    Pending

Phase II

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    LENTIVIRAL VECTOR CONTAINING THE HUMAN ABCA4 GENE
    2024-513501-31-00 1 country 2013 n=14 Orphan
    Ended

Phase I (Other)

1 trial
  • Bioinova a.s. Commercial
    IMP not specified
    2023-503573-38-00 1 country n=10
    Pending

Phase I (First in Human)

2 trials
  • Aavantgarde Bio S.r.l. Commercial
    COMBINATION OF TWO ADENO-ASSOCIATED VIRAL VECTORS OF SEROTYPE 8 CONTAINING THE 5'- AND THE 3'- HALF CODING SEQUENCES OF HUMAN ABCA4 FUSED TO INTEINS
    2025-522207-15-01 4 countries n=21
    Pending
  • Splicebio S.L. Commercial
    ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, N-REGION, ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, C-REGION
    2024-519535-42-00 2 countries n=13 Orphan
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Belite Bio Inc. Commercial 2 Phase III 0
Bioinova a.s. Commercial 1 Phase I (Other) 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II 0
Aavantgarde Bio S.r.l. Commercial 1 Phase I (First in Human) 0
Splicebio S.L. Commercial 1 Phase I (First in Human) 0
New trials by year
2022
1
← All indication landscapes